Lucid Capital Markets Starts Adagio Medical Holdings (ADGM) at Buy, PT $3, 'Underserved $5.8B Market Only 6% Penetrated'

Lucid Capital Markets analyst Alex Nowak initiates coverage on Adagio Medical Holdings (NASDAQ: ADGM) with a Buy rating and a price target of $3.00.

The analyst comments "Underserved $5.8B Market Only 6% Penetrated: Roughly 1.6M patients globally are eligible for ventricular tachycardia (VT) ablation annually, yet only ~100K procedures are performed WW. This is because every commercial catheter in use today was designed for atrial fibrillation (AF) and repurposed for the ventricle, driving up to an 11.5% complication rate that suppresses adoption. VT-associated sudden cardiac death accounts for ~300K U.S. deaths each year, and emerging Level 1 evidence from the VANISH-2 and PAUSE-SCD trials (which randomized patients with VT into either catheter ablation or antiarrhythmic drug therapy) is pushing ablation toward first-line therapy. The missing link is an ablation catheter that’s purpose built for VT. ADGM created this product with vCLAS. Combined with market dynamics, the stage is set for AF-like market acceleration off a base growing 5-8% today, with ADGM as the clear victor"

For an analyst ratings summary and ratings history on Adagio Medical Holdings click here. For more ratings news on Adagio Medical Holdings click here.

Shares of Adagio Medical Holdings closed at $0.78 yesterday.

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• Brean Capital Upgrades Columbia Financial Inc (CLBK) to Buy
• China e-commerce sees 3% growth in July, recovery expected Macquarie says